GlassScriptPhysician profile
Jay A Erlebacher
NPI 1285737080
$5,261.97
in general payments reported to CMS, 2019-2025
36 companies · $697 in 2025
The $697 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $393 · 2021: $311 · 2022: $624 · 2023: $1,067 · 2024: $847 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,610.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $975.39 | 2019-2025 | |
| Pfizer INC. | $842.81 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $567.38 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $296.95 | 2023-2024 | Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Janssen Pharmaceuticals, INC | $250.35 | 2020-2023 | Xarelto |
| Amgen INC. | $243.49 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $172.11 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $151.73 | 2021-2025 | Verquvo |
| Cvrx, INC. | $145.23 | 2022-2024 | Barostim Neo System |
| Bard Peripheral Vascular, INC. | $125.00 | 2019 | |
| Abbott Laboratories | $119.61 | 2020-2025 | Aveir |
| Alnylam Pharmaceuticals INC. | $112.61 | 2023-2025 | Amvuttra, Onpattro |
| Bardy Diagnostics, INC. | $107.58 | 2019-2020 | |
| Amarin Pharma, INC. | $104.72 | 2019-2022 | |
| Esperion Therapeutics, INC. | $102.47 | 2022-2025 | Nexletol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $100.91 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $94.01 | 2022-2025 | Mcot, (Ck4) Mcot |
| Lundbeck LLC | $86.06 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $84.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $83.27 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $81.58 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.18 | 2019-2025 | Jardiance |
| Abiomed | $56.86 | 2023-2024 | Impella |
| Heartflow, INC. | $40.72 | 2024-2025 | |
| Angiodynamics, INC. | $34.61 | 2019 | |
| Boston Scientific Corporation | $32.67 | 2019 | |
| Irhythm Technologies, INC. | $30.89 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Actelion Pharmaceuticals US, INC. | $27.76 | 2024 | Opsumit |
| Chiesi USA, INC. | $25.98 | 2019 | |
| Lilly USA, LLC | $19.37 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.20 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $15.85 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $15.00 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $14.52 | 2023 | Arcalyst |
| Portola Pharmaceuticals, LLC | $14.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Erlebacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.